Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management

The WHO Updated Diagnostic Criteria for MPNПодробнее

Differences and similarities between MDS and AML & how this can inform treatment decisionsПодробнее

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?Подробнее

Myelodysplastic syndromes - causes, symptoms, diagnosis, treatment, pathologyПодробнее

Use of Molecular Genetic Testing in MDS and MPNПодробнее

What’s the connection between myelodysplastic syndrome (MDS) and AML-MRC?Подробнее

What is the cause of MDS? #AMLПодробнее

Advances in Treating High Risk MDS and AMLПодробнее

Understanding Higher Risk MDS and Transtion to AMLПодробнее

MDS - Myeloplastic Syndromes - 2023 Best of Hematology ConferenceПодробнее

An Approach to Diagnosis and Staging of MDS: From Morphology to GeneticsПодробнее

The impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of HR AMLПодробнее

Understanding AMLПодробнее

Understanding the Recent WHO MDS Classification UpdatesПодробнее

Implementing MRD in clinical practice for patients with intermediate-risk AMLПодробнее

MPN Transformation to MDS and AML: Risk Factors, Therapy, and OutcomesПодробнее

Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classificationsПодробнее

How likely is it that MDS will progress to AML? and how long does it usually take? #AMLПодробнее

AML Treatment Challenges Who, When, and HowПодробнее

Myelodysplastic Syndrome (MDS) - What is the Treatment?Подробнее

The treatment protocol for higher risk MDSПодробнее